Table 3 Univariate analysis for overall survival and local control
Covariate categories | N | OS (%) | p | LC (%) | p | ||
|---|---|---|---|---|---|---|---|
3 years | 5 years | 3 years | 5 years | ||||
Age, years | |||||||
> 70 | 24 | 25.0 ± 8.8 | 16.7 ± 7.6 | 0.57 | 64.2 ± 4.7 | 64.2 ± 5.9 | 0.71 |
< 70 | 37 | 35.1 ± 7.8 | 18.9 ± 6.4 | 82.3 ± 4.4 | 82.3 ± 5.6 | ||
Gender | |||||||
Male | 35 | 20.6 ± 6.9 | 11.8 ± 5.5 | 0.01 | 78.1 ± 4.3 | 78.1 ± 5.4 | 0.97 |
Female | 26 | 44.4 ± 9.6 | 25.9 ± 8.4 | 81.8 ± 4.1 | 81.8 ± 5.4 | ||
Cancer type | |||||||
Colorectal | 29 | 41.1 ± 7.5 | 27.3 ± 8.1 | < 0.001 | 75.3 ± 4.7 | 75.3 ± 5.7 | 0.47 |
Breast cancer | 11 | 33.0 ± 7.3 | 20.1 ± 6.9 | 86.8 ± 4.8 | 86.8 ± 5.7 | ||
Gynecological cancer | 7 | 56.8 ± 6.9 | 27.8 ± 7.3 | 86.1 ± 4.7 | 86.1 ± 5.6 | ||
Other | 14 | 10.2 ± 7.2 | – | 80.0 ± 4.4 | – | ||
Number of metastases | |||||||
1 | 48 | 42.8 ± 13.2 | 28.6 ± 12.1 | 0.22 | 82.0 ± 4.5 | 82.0 ± 5.4 | 0.28 |
2–3 | 13 | 27.7 ± 6.5 | 14.9 ± 5.2 | 67.3 ± 4.7 | 67.3 ± 5.6 | ||
Size of metastases | |||||||
< 3 cm | 32 | 28.1 ± 7.9 | 15.6 ± 6.4 | 0.46 | 77.2 ± 4.3 | 77.2 ± 5.5 | 0.60 |
> 3 cm | 29 | 34.4 ± 8.8 | 20.7 ± 7.5 | 81.9 ± 4.3 | 81.9 ± 5.9 | ||
Timing of metastasis | |||||||
Synchronous | 24 | 29.3 ± 6.5 | 17.0 ± 5.5 | 0.93 | – | – | |
Metachronous | 37 | 32.2 ± 8.1 | 19.3 ± 6.9 | ||||
Time since diagnosis, mo | |||||||
≤ 12 | 35 | 31.4 ± 7.8 | 17.1 ± 6.4 | 0.91 | – | – | |
> 12 | 26 | 30.8 ± 9.0 | 19.2 ± 7.7 | ||||
Prior local therapy | |||||||
Yes | 27 | 33.3 ± 9.1 | 11.1 ± 6.1 | 0.54 | 65.8 ± 4.6 | 66.7 ± 5.7 | 0.06 |
No | 34 | 29.4 ± 7.8 | 23.5 ± 7.3 | 87.1 ± 4.8 | 87.1 ± 5.8 | ||
Pre-SBRT chemotherapy | |||||||
0–1 schedule | 23 | 43.5 ± 10.3 | 30.4 ± 9.6 | 0.10 | – | – | |
2–3-4 schedules | 38 | 23.7 ± 6.9 | 10.5 ± 5.0 | ||||
Extrahepatic disease | |||||||
Yes | 21 | 33.3 ± 10.3 | 14.3 ± 7.6 | 0.88 | – | – | |
No | 40 | 30.0 ± 7.2 | 20.0 ± 6.3 | ||||